Comparative Pharmacology
Head-to-head clinical analysis: CLINDAMYCIN HYDROCHLORIDE versus XACIATO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDAMYCIN HYDROCHLORIDE versus XACIATO.
CLINDAMYCIN HYDROCHLORIDE vs XACIATO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 50S ribosomal subunit, inhibiting peptide bond formation and bacterial protein synthesis.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby preventing peptide bond formation.
150-450 mg orally every 6 hours; maximum 1.8 g/day.
Administer one vaginal gel (50 mg clindamycin) intravaginally as a single dose.
None Documented
None Documented
The terminal elimination half-life of clindamycin is approximately 2-3 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life is prolonged to 8-12 hours. Renal impairment does not significantly alter half-life.
Terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. Half-life may be prolonged in patients with severe hepatic impairment or neonates.
Approximately 10-20% of clindamycin is excreted unchanged in urine; the remainder is hepatically metabolized and excreted in bile and feces as inactive metabolites. Fecal excretion accounts for about 4% of an administered dose as active drug and 60-70% as metabolites. Renal clearance is minor.
Clindamycin is primarily excreted via bile (approximately 85% of the dose as metabolites and parent drug) and feces (10%), with renal excretion accounting for less than 10%.
Category A/B
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic